FDA issues antidepressant suicide warning

被引：0

|

作者：

不详

机构：

来源：

PSYCHIATRIC ANNALS | 2004年 / 34卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

引用

收藏

页码：340 / 340

页数：1

相关论文

共 50 条

[31] The Suicide Epidemic in Youth and the FDA Black-Box Warning: Time to Reconsider
Nierenberg, Andrew A.
[J]. PSYCHIATRIC ANNALS, 2020, 50 (01) : 2 - 3
[32] FDA issues warning that paroxetine may increase the risk of birth defects
Wong, S
[J]. CNS SPECTRUMS, 2005, 10 (11) : 858 - 858
[33] US FDA issues warning against unapproved stem cell therapy
[J]. Reactions Weekly, 2018, 1684 (1) : 1 - 1
[34] FDA issues warning letters about unapproved eye disorder therapies
[J]. Reactions Weekly, 2023, 1975 (1) : 6 - 6
[35] FDA directs antidepressant manufacturers to add pediatric suicidality 'black box' warning to labelling
不详
[J]. FORMULARY, 2004, 39 (11) : 523 - 523
[36] Link between FDA antidepressant warnings and increased suicide attempts in young people is questionable
Olfson, Mark
Schoenbaum, Michael
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
[37] Proxy for suicide attempts was inappropriate in study of changes in antidepressant use after FDA warnings
Bartlett, Robert O.
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
[38] Study findings on FDA antidepressant warnings and suicide attempts in young people: a false alarm?
Barber, Catherine
Azrael, Deborah
Miller, Matthew
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
[39] US FDA issues PML warning after Tecfidera-related death
[J]. Reactions Weekly, 2014, 1530 (1) : 5 - 5
[40] FDA issues pioglitazone warning based on 5-year study results
[J]. Reactions Weekly, 2011, 1357 (1) : 2 - 2

← 1 2 3 4 5 →